Cytomegalovirus Viremia
3
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Determination Of Hcmv Dna In Plasma After Dnase Digestion
Research Leaders
8 sponsors active, led by Alberta Precision Laboratories
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
HCMV Breakthrough Infections During Letermovir Prophylaxis
Research Network
Common Treatments
- Determination Of Hcmv Dna In Plasma After Dnase Digestion1
- Cmvvst1
- Determination Of Hcmv Dna In Blood Or Plasma1
Active Sponsors
- Alberta Precision Laboratories1
- Fondazione IRCCS Policlinico San Matteo di Pavia1
- University of Alberta1
- Gruppo Italiano Trapianto di Midollo Osseo1
- Alberta Health services1
Top Investigators
Fondazione IRCCS Policlinico San Matteo
Azienda Policlinico Umberto I
Related Conditions
- Hematopoietic Stem Cell Transplantation1
- Herpesvirus Infection1
- Stem Cell Transplant Complications1
- Cytomegalovirus Pneumonia1
- Cytomegalovirus Infections1